Q-omics provides the consensus-scored ACAT2 profile across patient tissues and cancer cell-line models. ACAT2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ACAT2 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, ACAT2 protein abundance shows 25,238 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, KICH, and PDAC as cancer lineages where ACAT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACAT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACAT2 survival associations across molecular data types. ACAT2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACAT2 RNA expression–survival associations across cancer types. High ACAT2 expression shows unfavorable associations in MESO, KICH, LUAD, ACC, UVM and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ACAT2 RNA expression.
This table summarizes ACAT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 8. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ACAT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACAT2 shows lower tumor expression in KICH, THCA, KIRP and KIRC and higher tumor expression in BLCA and BRCA. The KICH box plot shows higher ACAT2 RNA expression in normal versus tumor tissue (log2 FC = −1.851, t-test p < 0.001).
This table shows molecular features associated with ACAT2 in patient tissues and cancer cell lines. In patient samples, ACAT2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACAT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
